bristar immunotech
Better T Cell Therapy
Better Patient Outcomes
bristar immunotech
IN CHINA
HELPING PATIENTS
GLOBALLY
bristar immunotech
PIONEERING CELLULAR
IMMUNOTHERAPIES
bristar immunotech
PATIENTS
FIRST
News
- 2026-06-02
Breaking News| First-in-Human Clinical Study of BristarImmunotech’s Dual-Epitope Anti-LILRB4 STAR‑T Published
Recently, the first-in-human clinical research paper regarding dual-epitope anti-LILRB4 STAR‑T for relapsed/refractory acute myeloid leukemia (R/R AML), jointly completed by BristarImmunotech, Peking University People’s Hospital and School of Basic Medical Sciences, Tsinghua University, has been formally accepted for publication by Signal Transduction and
- 2026-05-29
Press Preview| BristarImmunotech to Present Clinical Data of Off-the-Shelf Universal STAR-T at EULAR 2026
The Annual Congress of the European Alliance of Associations for Rheumatology (EULAR), one of the world’s top authoritative academic conferences in rheumatology and immunology, is set to kick off shortly. BristarImmunotech will present clinical findings of its universal CD19 STAR-T (YTS109) for severe/refractory autoimmune diseases via an abstract presentation, showcasing
- 2026-04-20
AACR Annual Meeting | BriSTAR Immunotech's Presents Clinical Progress of GPC3-Targeted STAR-T Cell Therapy at AACR 2026
Recently, the 2026 Annual Meeting of the American Association for Cancer Research (AACR), a globally influential academic event in oncology, was successfully held in San Diego, California, USA. Following the presentation of LILRB4-targeted STAR-T research data at AACR 2023, Sinocelltech once again made a major appearance on this top international academic stage. This
About us
BriSTAR Immunotech was founded in 2018 by globally renowned immunologists, and develops high-efficacy engineered T cell immunotherapy products for cancer and autoimmune diseases via proprietary STAR-T and off-the-shelf STAR-T platforms. The company has obtained 2 China IND clinical approvals and 1 FDA orphan drug designation; it has filed nearly 100 invention patents globally and been granted more than 10 Chinese invention patents and PCT patents. We will continue to accelerate the clinical translation and industrialization of our products, and drive the industrial upgrading of cellular therapy.
-
2018
Established In
-
60+
Employees
-
2000m²
37,600 sq.ft. R&D center
-
8+
Important Publications
Platform
Technology
Manufacturing
Pioneering Technology Platform
STAR-T & TCR-T
Technology
Pioneering Technology Platform
STAR-T & Off-the-shelf STAR-T
In vivo STAR-T
Manufacturing
Pipeline
The company is actively promoting the development of universal cell therapy products, treatments for autoimmune diseases, therapies for solid tumors, and new targets for hematologic tumor products.
READ MOREStay In Touch With BriSTAR Immunotech
Send our team your questions | Sign up to receive news updates